Rab Geranylgeranylation: a Novel Therapeutic Target in Multiple Myeloma

Ralph D Sanderson

Heparanase Regulation of Myeloma Metastasis: Mechanism and Therapy

Multiple myeloma and immunoproliferative diseases

Hematology and hematologic malignancies

Teru Hideshima

Functional and biologic significance of deacetylase3 inhibition in myeloma

Multiple myeloma and immunoproliferative diseases

Tracy L Mcgaha

The role of marginal zone macrophages and immuno-metabolism in tumor-driven MDSC development

Multiple myeloma and immunoproliferative diseases

Hematology and hematologic malignancies Pathology

Robert Zygmunt Orlowski

Role of TJP1 in Sensitivity and Resistance to Proteasome Inhibitors in Myeloma

Multiple myeloma and immunoproliferative diseases

William Figg

Using Clinical Pharmacology Principles to Develop New Anticancer Therapies

Multiple myeloma and immunoproliferative diseases

Pathology Hematology and hematologic malignancies

Catriona HM Jamieson

(PQC2) Niche-responsive RNA editing by ADAR1 in dormant multiple myeloma initiating cell maintenance

Multiple myeloma and immunoproliferative diseases

Hematology and hematologic malignancies Pathology

Elad Ziv

Influence of germ line genetic variation on myeloma progression and survival

Multiple myeloma and immunoproliferative diseases

Pathology Hematology and hematologic malignancies

Daniel M Sullivan

CRM1 INHIBITORS SENSITIZE MULTIPLE MYELOMA CELLS TO TOPOISOMERASE II AND PROTEASOME INHIBITORS

Multiple myeloma and immunoproliferative diseases

Kenneth C Anderson

Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications

Multiple myeloma and immunoproliferative diseases

Pathology Hematology and hematologic malignancies